Clinical Trials
7
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Study of ADG206 in Subjects With Advanced/Metastatic Solid Tumors
- First Posted Date
- 2022-11-14
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Adagene Inc
- Target Recruit Count
- 21
- Registration Number
- NCT05614258
- Locations
- 🇦🇺
Ashford Cancer Centre Research, Kurralta Park, South Australia, Australia
🇦🇺Monash Health, Clayton, Victoria, Australia
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
- Conditions
- Advanced/Metastatic Solid Tumors
- Interventions
- Drug: Standard of Care (Trifluridine/Tipiracil-Bevacizumab)Drug: Standard of care (Fruquintinib)
- First Posted Date
- 2022-06-06
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Adagene Inc
- Target Recruit Count
- 152
- Registration Number
- NCT05405595
- Locations
- 🇺🇸
Honor Health Research Institute, Scottsdale, Arizona, United States
🇺🇸Florida cancer specialist/Sarah Cannon Research Institute, Sarasota, Florida, United States
🇨🇳Fujian Cancer Hospital, Fuzhou, Fujian, China
ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
- First Posted Date
- 2022-03-14
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Adagene Inc
- Target Recruit Count
- 6
- Registration Number
- NCT05277402
- Locations
- 🇺🇸
Carolina BioOncology Institute, Huntersville, North Carolina, United States
🇺🇸Next Oncology, San Antonio, Texas, United States
ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors
- Conditions
- Advanced/Metastatic Solid Tumors
- First Posted Date
- 2020-11-27
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Adagene Inc
- Target Recruit Count
- 58
- Registration Number
- NCT04645069
- Locations
- 🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸Next oncology, San Antonio, Texas, United States
🇦🇺Southside Cancer Care Centre, Miranda, New South Wales, Australia
A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients
- Conditions
- Advanced/Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2020-08-06
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Adagene Inc
- Target Recruit Count
- 72
- Registration Number
- NCT04501276
- Locations
- 🇺🇸
Next Oncology, San Antonio, Texas, United States
🇦🇺Ashford Cancer Centre Research, Kurralta Park, Australia
🇦🇺Cabrini Hospital, Malvern, Australia
- Prev
- 1
- 2
- Next